Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna's Rally As MRNA Lands A Nasdaq ...

2 October 2026 · By · Wire by Fusion42

Published

2 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at es.tradingview.com →

◆ Verified

Fusion42 · 3 October 2026 · Fusion42 review

Moderna's imminent Nasdaq-100 inclusion and its cancer vaccine success have driven comparisons with biotech stocks Sellas Life Sciences (SLS) and ImmunityBio (IBRX), sparking renewed retail interest amid upcoming FDA decisions and clinical trial readouts.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Retail investors are tracking clinical trial milestones and FDA decisions closely due to Moderna's Nasdaq success. If you build biotech public market strategies, anticipate volatility and opportunity around cancer vaccine data and FDA label expansions.

◆ Coverage

1 source · 2 Oct 2026

◆ Related on Wire

◆ Topics

Biotechmodernabiotechnasdaq-100clinical-trialsfda-approval